Home・Listă Acțiuni・Arcus Biosciences Inc

Arcus Biosciences Inc

Deschisă

SectorSănătate

28.81 4.42

Cumpără Vinde

Rezumat

Modificarea prețului

24h

Curent

Minim

27.39

Maxim

28.58

Indicatori cheie
By Trading Economics
Venit	-22M -128M
Vânzări	-16M 17M
EPS	-1.02
Marjă de profit	-752.941
Angajați	601
EBITDA	-42M -123M

Recomandări
By TipRanks
Recomandări	Puternic Cumpărare
Prognoză pe 12 luni	+39.86% upside

Dividende
By Acuity
Următoarele câștiguri	5 aug. 2026

Statistici piață
By TradingEconomics
Capitalizare de piață	229M 3.5B
Deschiderea anterioară	24.39
Închiderea anterioară	28.81

Sentimentul știrilor

By Acuity

79%

21%

307 / 340 Clasament în Healthcare

Arcus Biosciences Inc Grafic

Performanțele din trecut nu reprezintă un indicator fiabil al rezultatelor viitoare.

Știri relevante

3 aug. 2026, 19:36 UTC

Arcus Biosciences shares are lower today, reflecting broader market dynamics and geopolitical developments impacting investor sentiment. Earlier, shares peaked before declining.

31 iul. 2026, 23:16 UTC

Arcus Biosciences Inc. shares are lower in after-market hours, continuing a trend of declining prices and remaining below the 20-day moving average.

30 iul. 2026, 18:03 UTC

Arcus Biosciences Inc gains today, supported by a broader market uptick despite geopolitical tensions and inflation concerns. Shares pulled back from earlier session highs.

29 iul. 2026, 19:56 UTC

Macro Event

Arcus Biosciences shares are lower amid broader market pressures from steady interest rates and rising crude oil prices, marking five consecutive sessions of decline.

28 iul. 2026, 20:06 UTC

Arcus Biosciences Inc shares are lower today, reflecting broader market trends and declines in Asian markets, including significant losses in the Nikkei 225 Index.

27 iul. 2026, 21:01 UTC

Arcus Biosciences Inc shares declined in after-market hours, continuing a downward trend over the last four sessions. No specific news was identified to explain the move.

24 iul. 2026, 19:06 UTC

News

Arcus Biosciences has signed a clinical supply agreement with AVEO to evaluate casdatifan with tivozanib. Shares are trading lower, reflecting unusual weakness.

22 iul. 2026, 20:13 UTC

Arcus Biosciences shares are higher in after-market hours. Broader market volatility is influenced by rising crude oil prices and geopolitical tensions.

21 iul. 2026, 19:36 UTC

Arcus Biosciences shares are higher today, supported by overall market strength and positive sentiment in the biotechnology sector. The stock has advanced notably since Monday.

20 iul. 2026, 18:06 UTC

News

H.C. Wainwright raised Arcus Biosciences' price target to $45 from $32, maintaining a Buy rating. Shares are higher today following the analyst's upgrade.

Comparație

Modificare preț

Arcus Biosciences Inc Așteptări

Obiectiv de preț

By TipRanks

39.86% sus

Prognoză pe 12 luni

Medie 38.63 USD 39.86%

Maxim 47 USD

Minim 22 USD

În baza a 9 analiști de pe Wall Street care oferă obiective de preț pe 12 luni pentruArcus Biosciences Inc - Dist în ultimele 3 luni.

Consens privind evaluarea

By TipRanks

Puternic Cumpărare

9 ratings

Cumpărare

Păstrare

Vânzare

Ținând cont de 9 analiști care au acordat evaluări ale acțiunilor Arcus Biosciences Inc - Dist în ultimele 3 luni.

Sentiment

By Acuity

307 / 340 Clasament în Sănătate

Date financiare

Cheltuieli de vânzare și administrare

Cheltuieli de exploatare

Profit pre-impozitare

Vânzări

Costul vânzărilor

Profit brut din vânzări

Cheltuieli cu dobânzile pe datorie

EBITDA

Profit operațional

Despre Arcus Biosciences Inc

Arcus Biosciences, Inc., a clinical-stage biopharmaceutical company, develops and commercializes cancer therapies in the United States. The company's pipeline products include Domvanalimab, an anti-TIGIT antibody, which is in Phase 2 and Phase 3 clinical trial; and AB308, an investigational anti-TIGIT monoclonal antibody, which is in Phase 1b clinical trial to study people with advanced solid and hematologic malignancies. It also develops Etrumadenant, a dual A2a/A2b adenosine receptor antagonist, which is in Phase 2 clinical trial; Quemliclustat, a small-molecule CD73 inhibitor, which is Phase 1b and Phase 2 clinical trial; Zimberelimab, an anti-PD-1 antibody, which is in Phase 2 clinical trial for metastatic cell lung cancer and monotherapy; and AB521, an oral and small-molecule inhibitor of HIF-2a, which is in Phase 1 clinical trial for the treatment of Von Hippel-Lindau disease. In addition, the company's preclinical pipeline products include AB598, a CD39 antibody; and AB801, a small molecule Axl inhibitor. It has a clinical collaboration with AstraZeneca to evaluate domvanalimab in combination with durvalumab in a registrational phase 3 clinical trial in patients with unresectable Stage 3 NSCLC; and BVF Partners L.P. to support the discovery and development of compounds for the treatment of inflammatory diseases. Arcus Biosciences, Inc. was incorporated in 2015 and is headquartered in Hayward, California.